{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:58:08Z","timestamp":1792173488089,"version":"4.4.0"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mirtazapine is widely used in the treatment of major depressive disorder (MDD), yet its real-world safety profile remains insufficiently evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study analyzed adverse event (AE, plural AEs) reports related to mirtazapine from the FDA Adverse Event Reporting System (FAERS) database between the first quarter of 2004 and the first quarter of 2025. Four disproportionality analysis methods were employed, including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS). Additional analyses included sensitivity analysis, time-to-onset (TTO) evaluation, and Weibull distribution modeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 17,953 reports were included, with females accounting for 54.1% and males for 37.7%. In 48.4% of the reports, patients were aged between 18 and 65 years. Overall, 65.0% of the reports were submitted by healthcare professionals. Known AEs such as somnolence (n\u2009=\u2009887, ROR\u2009=\u20094.57, PRR\u2009=\u20094.52, EBGM\u2009=\u20094.50, IC\u2009=\u20092.17), QT interval prolongation (n\u2009=\u2009259, ROR\u2009=\u20097.35, PRR\u2009=\u20097.32, EBGM\u2009=\u20097.27, IC\u2009=\u20092.86), suicidal ideation (n\u2009=\u2009601, ROR\u2009=\u20096.65, PRR\u2009=\u20096.59, EBGM\u2009=\u20096.55, IC\u2009=\u20092.71), and rhabdomyolysis (n\u2009=\u2009146, ROR\u2009=\u20093.66, PRR\u2009=\u20093.65, EBGM\u2009=\u20093.64, IC\u2009=\u20091.87) showed positive signals. In addition, several unexpected AEs also exhibited positive signals, including restless legs syndrome (n\u2009=\u2009305, ROR\u2009=\u200917.05, PRR\u2009=\u200916.97, EBGM\u2009=\u200916.65, IC\u2009=\u20094.06), neuroleptic malignant syndrome (n\u2009=\u2009158, ROR\u2009=\u200913.77, PRR\u2009=\u200913.74, EBGM\u2009=\u200913.53, IC\u2009=\u20093.76), and nightmare (n\u2009=\u2009279, ROR\u2009=\u20098.02, PRR\u2009=\u20097.99, EBGM\u2009=\u20097.93, IC\u2009=\u20092.99). TTO analysis showed that 59.52% of AEs occurred within the first month of treatment. The results of the sensitivity analyses further supported the robustness of these findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study systematically assessed the long-term safety profile of mirtazapine using 21 years of real-world pharmacovigilance data from the FAERS database. The findings provide important evidence to support safe clinical use of mirtazapine and emphasize the need for continuous safety monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0340092","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:34:04Z","timestamp":1772822044000},"page":"e0340092","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term safety evaluation of mirtazapine: A real-world pharmacovigilance study based on the FAERS database"],"prefix":"10.1371","volume":"21","author":[{"given":"Kaidi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4451-7573","authenticated-orcid":true,"given":"Jiashu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"issue":"10312","key":"pone.0340092.ref001","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(21)02143-7","article-title":"Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic","volume":"398","author":"COVID-19 Mental Disorders Collaborators","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"pone.0340092.ref002","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1017\/S1092852918001207","article-title":"Cognitive impairment in major depressive disorder","volume":"24","author":"Z Pan","year":"2019","journal-title":"CNS Spectr"},{"key":"pone.0340092.ref003","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2147\/NDT.S159276","article-title":"Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study","volume":"14","author":"D Saragoussi","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"pone.0340092.ref004","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3390\/medicina61040558","article-title":"Pharmacological Monotherapy for Depressive Disorders: Current and Future-A Narrative Review","volume":"61","author":"K Gao","year":"2025","journal-title":"Medicina (Kaunas)"},{"issue":"5","key":"pone.0340092.ref005","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1007\/s00210-023-02818-6","article-title":"Pharmacological update of mirtazapine: a narrative literature review","volume":"397","author":"EHM Hassanein","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"3","key":"pone.0340092.ref006","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0165-0327(98)00224-9","article-title":"Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression","volume":"51","author":"J Fawcett","year":"1998","journal-title":"J Affect Disord"},{"issue":"10128","key":"pone.0340092.ref007","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"A Cipriani","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"pone.0340092.ref008","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1176\/appi.ajp.2009.09020186","article-title":"Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study","volume":"167","author":"P Blier","year":"2010","journal-title":"Am J Psychiatry"},{"issue":"11","key":"pone.0340092.ref009","first-page":"519","article-title":"A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression","volume":"56","author":"JD Bremner","year":"1995","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"pone.0340092.ref010","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0006-3223(01)01262-8","article-title":"A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine","volume":"51","author":"LL Carpenter","year":"2002","journal-title":"Biol Psychiatry"},{"issue":"2","key":"pone.0340092.ref011","article-title":"Rhabdomyolysis Associated With Mirtazapine and Quetiapine Therapy: A Case Report and Review of the Literature","volume":"16","author":"G Heng","year":"2024","journal-title":"Cureus"},{"issue":"3","key":"pone.0340092.ref012","first-page":"329","article-title":"Antipsychotic induced rhabdomyolysis","volume":"76","author":"C Ratnam","year":"2018","journal-title":"Ann Biol Clin (Paris)"},{"issue":"4","key":"pone.0340092.ref013","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/WNF.0b013e318187bafc","article-title":"New onset somnambulism associated with different dosage of mirtazapine: a case report","volume":"32","author":"Y-W Yeh","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"pone.0340092.ref014","doi-asserted-by":"crossref","first-page":"119517","DOI":"10.1016\/j.jad.2025.119517","article-title":"Uncovering safety signals of duloxetine: Real-world evidence from the FAERS database","volume":"388","author":"D Liu","year":"2025","journal-title":"J Affect Disord"},{"key":"pone.0340092.ref015","doi-asserted-by":"crossref","first-page":"1458438","DOI":"10.3389\/fphar.2024.1458438","article-title":"Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data","volume":"15","author":"K Zhao","year":"2024","journal-title":"Front Pharmacol"},{"key":"pone.0340092.ref016","doi-asserted-by":"crossref","first-page":"132305","DOI":"10.1016\/j.ijcard.2024.132305","article-title":"Safety evaluation of bempedoic acid: A pharmacovigilance analysis using FDA adverse event reporting system data","volume":"412","author":"B Li","year":"2024","journal-title":"Int J Cardiol"},{"key":"pone.0340092.ref017","doi-asserted-by":"crossref","first-page":"1702875","DOI":"10.3389\/fphar.2025.1702875","article-title":"The real-world safety profile of ranolazine: pharmacovigilance analysis of the FAERS database","volume":"16","author":"Z Wen","year":"2025","journal-title":"Front Pharmacol"},{"issue":"3","key":"pone.0340092.ref018","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0165-0327(95)00014-E","article-title":"A double-blind placebo-controlled study of Org 3770 in depressed outpatients","volume":"34","author":"JL Claghorn","year":"1995","journal-title":"J Affect Disord"},{"key":"pone.0340092.ref019","doi-asserted-by":"crossref","first-page":"102113","DOI":"10.1016\/j.smrv.2025.102113","article-title":"Shedding light on microsleep episodes for comprehensive sleepiness assessment: a narrative review","volume":"82","author":"A Davin","year":"2025","journal-title":"Sleep Med Rev"},{"issue":"2","key":"pone.0340092.ref020","doi-asserted-by":"crossref","first-page":"102938","DOI":"10.1016\/j.neucli.2023.102938","article-title":"Objective evaluation of excessive daytime sleepiness","volume":"54","author":"J Taillard","year":"2024","journal-title":"Neurophysiol Clin"},{"issue":"4","key":"pone.0340092.ref021","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/psyg.12520","article-title":"Mirtazapine-induced long QT syndrome in an elderly patient: a case report","volume":"20","author":"Y Matsuda","year":"2020","journal-title":"Psychogeriatrics"},{"issue":"6","key":"pone.0340092.ref022","article-title":"Malignant Catatonia Versus Neuroleptic Malignant Syndrome","volume":"13","author":"S Desai","year":"2021","journal-title":"Cureus"},{"key":"pone.0340092.ref023","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12991-015-0073-z","article-title":"Neurotoxic syndrome induced by clomipramine plus risperidone in a patient with autistic spectrum disorder: serotonin or neuroleptic malignant syndrome?","volume":"14","author":"KN Nikolaou","year":"2015","journal-title":"Ann Gen Psychiatry"},{"issue":"3","key":"pone.0340092.ref024","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.parkreldis.2010.11.007","article-title":"Forme fruste of neuroleptic malignant syndrome associated with the use of sertraline","volume":"17","author":"M Miranda","year":"2011","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"pone.0340092.ref025","doi-asserted-by":"crossref","first-page":"587","DOI":"10.24869\/psyd.2023.587","article-title":"ATYPICAL NEUROLEPTIC MALIGNANT SYNDROME ASSOCIATED WITH MIRTAZAPINE USE","volume":"35","author":"T A\u011fa\u00e7","year":"2023","journal-title":"Psychiatr Danub"},{"issue":"4","key":"pone.0340092.ref026","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1002\/ccr3.4049","article-title":"Neuroleptic malignant syndrome in a patient with moderate intellectual disability treated with olanzapine: A case report","volume":"9","author":"F Piacenza","year":"2021","journal-title":"Clin Case Rep"},{"issue":"1","key":"pone.0340092.ref027","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0269881103017001716","article-title":"The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13554 patients in England","volume":"17","author":"PN Biswas","year":"2003","journal-title":"J Psychopharmacol"},{"key":"pone.0340092.ref028","doi-asserted-by":"crossref","first-page":"1637471","DOI":"10.3389\/fpsyt.2025.1637471","article-title":"Arrhythmic events pertinent with antidepressants: a Bayesian disproportional analysis mining the FDA Adverse Event Reporting System database","volume":"16","author":"S Cao","year":"2025","journal-title":"Front Psychiatry"},{"issue":"1","key":"pone.0340092.ref029","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12888-024-06396-6","article-title":"The risks of adverse events with mirtazapine for adults with major depressive disorder: a systematic review with meta-analysis and trial sequential analysis","volume":"25","author":"CB Kamp","year":"2025","journal-title":"BMC Psychiatry"},{"key":"pone.0340092.ref030","doi-asserted-by":"crossref","first-page":"1689634","DOI":"10.3389\/fphar.2025.1689634","article-title":"Disproportionality evaluation of adverse effects and suicide\/self-injury risk factors associated with vortioxetine: a large-scale pharmacovigilance study","volume":"16","author":"X Li","year":"2025","journal-title":"Front Pharmacol"},{"key":"pone.0340092.ref031","doi-asserted-by":"crossref","first-page":"1693090","DOI":"10.3389\/fphar.2025.1693090","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for etrasimod","volume":"16","author":"Y Wu","year":"2025","journal-title":"Front Pharmacol"},{"issue":"1","key":"pone.0340092.ref032","doi-asserted-by":"crossref","first-page":"42218","DOI":"10.1038\/s41598-025-26340-2","article-title":"Post marketing safety surveillance of atezolizumab based on a retrospective analysis of the FDA adverse events reporting system (FAERS)","volume":"15","author":"G Zhang","year":"2025","journal-title":"Sci Rep"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:34:09Z","timestamp":1772822049000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340092"}},"subtitle":[],"editor":[{"given":"Hira","family":"Rafi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0340092","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]}}}